Kazia begins phase II study into paxalisib + a keto diet to treat brain cancer

AdobeStock_261939312

Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)

Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)